Leonardo Fleury Orlandini
Leonardo Fleury Orlandini has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Guimarães Tiezzi
Universidade de São Paulo
4 shared publications - Jurandyr Moreira de Andrade
Department of Gynecology and Obstetrics, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil
4 shared publications - Francisco José Candido dos Reis
Universidade de São Paulo, Brasil
3 shared publications - Franklin Fernandes Pimentel
Universidade de São Paulo
3 shared publications - Augusto Tufi Hassan
Sociedade Brasileira de Mastologia
1 shared publication - Beatriz Baaklini Geronymo
Beneficência Portuguesa de São Paulo
1 shared publication
Latest Publications
- Open Access
Consensus from the 2025 International Symposium on Breast Diseases of Inland São Paulo: Management of HER2-Positive Breast Cancer
Objective: To present the expert panel recommendations derived from the panel discussion “Management of HER2-Positive Breast Cancer”, held during the 2025 International Symposium on Breast Diseases of Inland São Paulo (SIMIP), addressing critical controversies in treatment. Methods: Priority topics were discussed in evidence-based lectures, followed by technical debates and anonymous electronic voting among 110 panelists. Consensus was defined as agreement of ≥75%. Panelists were predominantly mastologists (101), of whom 94 were from São Paulo (Southeast) and seven from other regions: one from Bahia (Northeast), two from Rio Grande do Sul (South), one from Minas Gerais, two from Goiás (Central-West), and one from Ceará (Northeast). The panel also included six oncologists, two pathologists, and one radiotherapist, all from São Paulo. Panelists disclosed no relevant conflicts of interest related to human epidermal growth factor receptor 2 (HER2)-targeted therapies. Lectures were based on selected literature from existing clinical practice guidelines and pivotal clinical trials; no prior systematic review was conducted. The number of respondents varied across questions because voting participation was optional for each item, and the exact number of votes for each question was presented in the respective results tables. The questionnaire consisted of single-choice, forced-response items using binary or categorical formats, depending on the topic (not a Likert scale). The consensus process followed a structured expert panel methodology with anonymous electronic voting, but the number of respondents per question could vary. Results: The majority of respondents (64%) concluded that there is no standardization for HER2-low and ultra-low categories. For adjuvant therapy, 67% defined >5 mm (starting at T1bN0) as the threshold for indication. Neoadjuvant chemotherapy was recommended for tumors ≥2 cm by 68% of specialists. The HER2 genomic/prognosis test (DX) does not significantly alter management, according to 55% of votes. Conclusions: These expert consensus statements reflect current evidence and the majority views of the panel, supporting the management of HER2-positive breast cancer, with emphasis on multidisciplinary evaluation. Standardization of HER2-low and ultra-low categories and the clinical utility of HER2DX require further validation. These statements represent the majority opinion of Brazilian specialists and are intended to support clinical reasoning rather than define mandatory protocols or formal clinical practice guidelines.
Open AccessConsensus from the 2025 International Symposium on Breast Diseases of Inland São Paulo: Management of HER2-Positive Breast Cancer
Objective: To present the expert panel recommendations derived from the panel discussion “Management of HER2-Positive Breast Cancer”, held during the 2025 International Symposium on Breast Diseases of Inland São Paulo (SIMIP), addressing critical controversies in treatment. Methods: Priority topics were discussed in evidence-based lectures, followed by technical debates and anonymous electronic voting among 110 panelists. Consensus was defined as agreement of ≥75%. Panelists were predominantly mastologists (101), of whom 94 were from São Paulo (Southeast) and seven from other regions: one from Bahia (Northeast), two from Rio Grande do Sul (South), one from Minas Gerais, two from Goiás (Central-West), and one from Ceará (Northeast). The panel also included six oncologists, two pathologists, and one radiotherapist, all from São Paulo. Panelists disclosed no relevant conflicts of interest related to human epidermal growth factor receptor 2 (HER2)-targeted therapies. Lectures were based on selected literature from existing clinical practice guidelines and pivotal clinical trials; no prior systematic review was conducted. The number of respondents varied across questions because voting participation was optional for each item, and the exact number of votes for each question was presented in the respective results tables. The questionnaire consisted of single-choice, forced-response items using binary or categorical formats, depending on the topic (not a Likert scale). The consensus process followed a structured expert panel methodology with anonymous electronic voting, but the number of respondents per question could vary. Results: The majority of respondents (64%) concluded that there is no standardization for HER2-low and ultra-low categories. For adjuvant therapy, 67% defined >5 mm (starting at T1bN0) as the threshold for indication. Neoadjuvant chemotherapy was recommended for tumors ≥2 cm by 68% of specialists. The HER2 genomic/prognosis test (DX) does not significantly alter management, according to 55% of votes. Conclusions: These expert consensus statements reflect current evidence and the majority views of the panel, supporting the management of HER2-positive breast cancer, with emphasis on multidisciplinary evaluation. Standardization of HER2-low and ultra-low categories and the clinical utility of HER2DX require further validation. These statements represent the majority opinion of Brazilian specialists and are intended to support clinical reasoning rather than define mandatory protocols or formal clinical practice guidelines.
- Open Access
- 26 July 2024
- Published by Federação das Associações de Ginecologia e Obstetrícia in Revista Brasileira de Ginecologia e Obstetrícia
- Vol. 46
Real-world data on adjuvant capecitabine after standard neoadjuvant chemotherapy for triple negative breast cancer
Objective Neoadjuvant chemotherapy (NACT) has become the standard of care for patients with triple-negative breast cancer (TNBC) with tumors > 1 cm or positive axillary nodes. Pathologic complete response (pCR) has been used as an endpoint to select patients for treatment scaling. This study aimed to examine the benefit of adding adjuvant capecitabine for […] Abstract Objective Neoadjuvant chemotherapy (NACT) has become the standard of care for patients with triple-negative breast cancer (TNBC) with tumors > 1 cm or positive axillary nodes. Pathologic complete response (pCR) has been used as an endpoint to select patients for treatment scaling. This study aimed to examine the benefit of adding adjuvant capecitabine for […]
- 26 July 2024
- Published by Federação das Associações de Ginecologia e Obstetrícia in Revista Brasileira de Ginecologia e Obstetrícia
- Vol. 46
Open AccessReal-world data on adjuvant capecitabine after standard neoadjuvant chemotherapy for triple negative breast cancer
Objective Neoadjuvant chemotherapy (NACT) has become the standard of care for patients with triple-negative breast cancer (TNBC) with tumors > 1 cm or positive axillary nodes. Pathologic complete response (pCR) has been used as an endpoint to select patients for treatment scaling. This study aimed to examine the benefit of adding adjuvant capecitabine for […] Abstract Objective Neoadjuvant chemotherapy (NACT) has become the standard of care for patients with triple-negative breast cancer (TNBC) with tumors > 1 cm or positive axillary nodes. Pathologic complete response (pCR) has been used as an endpoint to select patients for treatment scaling. This study aimed to examine the benefit of adding adjuvant capecitabine for […]
Clinicopathological characteristics and recurrence risk in patients with ductal carcinoma in situ of the breast
Introduction: With the widespread adoption of mammographic screening for breast cancer, ductal carcinoma in situ (DCIS) has been detected more frequently. In developing countries, the prevalence of ductal carcinoma in situ is low due to the opportunistic nature of breast cancer screening. The aim of this study was to evaluate the clinicopathological characteristics and recurrence rate in a cohort of patients with ductal carcinoma in situ in Brazil. Methods: This study was an retrospective analysis of all 1,736 patients with non-metastatic breast cancer treated at a reference public hospital between 1999 and 2013. All data were collected from medical records and the descriptive statistics were performed to characterize the clinical and pathological features. Results: In the present cohort, we identified 102 (5.2%) patients with non-invasive breast neoplasms. Mean age at diagnosis was 54±12.7 years and most patients were treated with breast conserving surgery. There is a strong association between nuclear grade and the expression of estrogen and progesterone receptors in ductal carcinoma in situ. Ipsilateral and contralateral recurrence rates in 10 years were 7.2% and 2%, respectively. Conclusion: The pathological features of ductal carcinoma in situ diagnosed in Brazil are similar to those observed in patients diagnosed in countries following a systematic screening program, and the treatment in our patients achieves similar success compared with published data in high-income countries.
Clinicopathological characteristics and recurrence risk in patients with ductal carcinoma in situ of the breast
Introduction: With the widespread adoption of mammographic screening for breast cancer, ductal carcinoma in situ (DCIS) has been detected more frequently. In developing countries, the prevalence of ductal carcinoma in situ is low due to the opportunistic nature of breast cancer screening. The aim of this study was to evaluate the clinicopathological characteristics and recurrence rate in a cohort of patients with ductal carcinoma in situ in Brazil. Methods: This study was an retrospective analysis of all 1,736 patients with non-metastatic breast cancer treated at a reference public hospital between 1999 and 2013. All data were collected from medical records and the descriptive statistics were performed to characterize the clinical and pathological features. Results: In the present cohort, we identified 102 (5.2%) patients with non-invasive breast neoplasms. Mean age at diagnosis was 54±12.7 years and most patients were treated with breast conserving surgery. There is a strong association between nuclear grade and the expression of estrogen and progesterone receptors in ductal carcinoma in situ. Ipsilateral and contralateral recurrence rates in 10 years were 7.2% and 2%, respectively. Conclusion: The pathological features of ductal carcinoma in situ diagnosed in Brazil are similar to those observed in patients diagnosed in countries following a systematic screening program, and the treatment in our patients achieves similar success compared with published data in high-income countries.
- Open Access
- 1 January 2021
- Published by Mastology
- p. 38
HIGH NEUTROPHIL-TO-LYMPHOCYTE RATIO IS PROGNOSTIC FACTOR IN EARLY-STAGE BREAST CANCER PATIENTS
- 1 January 2021
- Published by Mastology
- p. 38
Open AccessHIGH NEUTROPHIL-TO-LYMPHOCYTE RATIO IS PROGNOSTIC FACTOR IN EARLY-STAGE BREAST CANCER PATIENTS
- Open Access
- 1 January 2021
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Medical and Biological Research
- Vol. 54 (10) , e11409
Obesity and high neutrophil-to-lymphocyte ratio are prognostic factors in non-metastatic breast cancer patients
Obesity has been associated with an increased risk of breast cancer recurrence and death. Some readily available biomarkers associated with systemic inflammation have been receiving attention as potential prognostic indicators in cancer, including neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR). This study aimed to explore the correlation between body mass index (BMI) and invasive breast cancer and the association of NLR, PLR, and BMI with breast cancer outcomes. We undertook a retrospective study to evaluate patients treated for breast cancer over 14 years. Clinicopathological data was obtained before receiving any treatment. Of the 1664 patients included with stage I-III, 567 (34%) were obese (BMI≥30 kg/m2). Obese patients had larger tumors compared to non-obese patients. Higher BMI was associated with recurrence and worse survival only in patients with stage I disease. NLR and PLR were classified into high and low level groups. The NLRhigh (NLR>4) was found to be an independent prognostic factor for recurrence and mortality, while the PLRhigh (PLR>150) group had no impact on survival. A subgroup of patients with NLRhigh and BMIhigh had the worst disease-free survival (P=0.046), breast cancer-specific survival (P<0.001), and overall survival (P=0.006), compared to the other groups. Patients with early-stage breast cancer bearing NLRhigh and BMIhigh had worse outcomes, and this might be explained by the dysfunctional milieu of obesity in adipose tissue and its effects on the immune system. This study highlights the importance of lifestyle measures and the immune system interference with clinical outcomes in the early breast cancer setting.
- 1 January 2021
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Medical and Biological Research
- Vol. 54 (10) , e11409
Open AccessObesity and high neutrophil-to-lymphocyte ratio are prognostic factors in non-metastatic breast cancer patients
Obesity has been associated with an increased risk of breast cancer recurrence and death. Some readily available biomarkers associated with systemic inflammation have been receiving attention as potential prognostic indicators in cancer, including neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR). This study aimed to explore the correlation between body mass index (BMI) and invasive breast cancer and the association of NLR, PLR, and BMI with breast cancer outcomes. We undertook a retrospective study to evaluate patients treated for breast cancer over 14 years. Clinicopathological data was obtained before receiving any treatment. Of the 1664 patients included with stage I-III, 567 (34%) were obese (BMI≥30 kg/m2). Obese patients had larger tumors compared to non-obese patients. Higher BMI was associated with recurrence and worse survival only in patients with stage I disease. NLR and PLR were classified into high and low level groups. The NLRhigh (NLR>4) was found to be an independent prognostic factor for recurrence and mortality, while the PLRhigh (PLR>150) group had no impact on survival. A subgroup of patients with NLRhigh and BMIhigh had the worst disease-free survival (P=0.046), breast cancer-specific survival (P<0.001), and overall survival (P=0.006), compared to the other groups. Patients with early-stage breast cancer bearing NLRhigh and BMIhigh had worse outcomes, and this might be explained by the dysfunctional milieu of obesity in adipose tissue and its effects on the immune system. This study highlights the importance of lifestyle measures and the immune system interference with clinical outcomes in the early breast cancer setting.